Baseline characteristics of study patients (n = 213)
| Characteristic . | . |
|---|---|
| Median age at study entry, y (25th–75th percentile) | 55 (44-66) |
| Sex, n (%) | |
| Female | 79 (37.1) |
| Male | 134 (62.9) |
| Brain tumor type, n (%) | |
| Glioblastoma/gliosarcoma (WHO grade IV), n (%) | |
| Glioblastoma | 150 (70.4) |
| Gliosarcoma | 2 (0.9) |
| Anaplastic glioma (WHO grade III), n (%) | |
| Anaplastic astrocytoma | 30 (14.1) |
| Anaplastic oligodendroglioma | 7 (3.3) |
| Anaplastic ependymoma | 1 (0.5) |
| Low-grade glioma (WHO grade II), n (%) | |
| Diffuse astrocytoma | 8 (3.8) |
| Diffuse oligodendroglioma | 2 (0.9) |
| Other, n (%) | |
| Medulloblastoma | 3 (1.4) |
| Primitive neuroectodermal tumor | 3 (1.4) |
| Anaplastic/atyptical meningioma | 3 (1.4) |
| Olfactory neuroblastoma | 2 (0.9) |
| Pineal tumor | 1 (0.5) |
| Gangliocytoma | 1 (0.5) |
| Characteristic . | . |
|---|---|
| Median age at study entry, y (25th–75th percentile) | 55 (44-66) |
| Sex, n (%) | |
| Female | 79 (37.1) |
| Male | 134 (62.9) |
| Brain tumor type, n (%) | |
| Glioblastoma/gliosarcoma (WHO grade IV), n (%) | |
| Glioblastoma | 150 (70.4) |
| Gliosarcoma | 2 (0.9) |
| Anaplastic glioma (WHO grade III), n (%) | |
| Anaplastic astrocytoma | 30 (14.1) |
| Anaplastic oligodendroglioma | 7 (3.3) |
| Anaplastic ependymoma | 1 (0.5) |
| Low-grade glioma (WHO grade II), n (%) | |
| Diffuse astrocytoma | 8 (3.8) |
| Diffuse oligodendroglioma | 2 (0.9) |
| Other, n (%) | |
| Medulloblastoma | 3 (1.4) |
| Primitive neuroectodermal tumor | 3 (1.4) |
| Anaplastic/atyptical meningioma | 3 (1.4) |
| Olfactory neuroblastoma | 2 (0.9) |
| Pineal tumor | 1 (0.5) |
| Gangliocytoma | 1 (0.5) |